This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
It appears that all the patients included in the study have been accounted for in the analysis of effectiveness. The health outcomes used in the study were:
the total anaesthesia and surgery times, the number of autologous units procured, intraoperative blood loss, red blood cell (RBC) loss, complete blood count, reticulocyte count, Hct levels, and autologous and allogeneic blood units transfused.
The study groups appear to have been comparable at baseline in terms of age, gender, weight distributions and mean Hct levels.
Effectiveness results
There were no statistically significant differences between the two groups in the following: total anaesthesia, (p=0.84) and surgery times, (p=0.69), the number of autologous units procured, (p=0.72), the estimated intraoperative blood losses, (p=0.29), or the calculated RBC losses for surgical hospitalisation, (p=0.74).
In patients undergoing ANH, the systolic, diastolic and mean arterial blood pressures were statistically lower after phlebotomy of 1 and 2 units than at baseline, (p<0.05), without changes in heart rate.
On the day of surgery, the Hct levels were lower in the PABD group than in the ANH group. The mean Hct (+/-the standard deviation, SD) was 37.0 (+/-4.0) in the PABD group versus 40.0 (+/-3.7) in the ANH group, (p=0.02). Subsequent Hct levels were significantly lower in the ANH group until discharge.
No difference was found in allogeneic blood exposure among ANH (17%) and PABD (0%) cohorts, (p=0.30). However, the mean number of allogeneic units transfused, 0.4 (+/-0.9) versus 0, reached statistical significance, (p=0.03).
Direct costs
The perspective of the study was not reported. The categories of costs included in the analysis were blood procurement from the regional blood centre, laboratory processing, administration, professional fees, and overheads. The resource use data were estimated using actual data coming from the sample of patients involved in the effectiveness study. The unit costs and the quantities of resources used were presented separately. The source of the unit costs and the price year were not reported. Discounting was not relevant since the costs were incurred during less than 2 years.
Statistical analysis of costs
The costs were presented as mean values with SDs. Statistical tests were conducted to compare the costs observed in the study groups.
Indirect Costs
No indirect costs were included.
Currency

US dollars ($).
Sensitivity analysis
Sensitivity analyses were not performed.
Estimated benefits used in the economic analysis
Not applicable.
Cost results
The total costs for blood were $151 (+/-154) in the ANH group and $680 (+/-253) in the PABD group. The ANH procedure was significantly less costly than PABD, (p<0.05).
